The Power of Genomics in Oncology

Explore genomic innovations driving precision oncology through our library of educational resources, developed by Illumina’s Medical Affairs team. ​

 

Innovations in your Inbox

Stay updated effortlessly. Sign up for our oncology insights

SubscribeOpens in a new window.

Comprehensive Genomic Profiling - Tissue

Video Hub

What are the benefits of in house CGP vs send out?

Caterina Marchiò, MD, PhD explains the benefits of performing in-house CGP testing vs test send-out to increase the opportunities for precision medicine for cancer patients.

How can in house CGP HRD benefit pancreatic cancer patients?

Nicole Pfarr, Dipl.-Biol, discusses how an in-house comprehensive genomic profiling (CGP) including HRD provides fast turnaround to guide patient treatment and improves laboratory operational efficiency.

HRD testing in ovarian cancer

Isabelle Ray-Coquard, MD, PhD, explains how comprehensive genomic profiling (CGP) simultaneously provides HRD and BRCA status in ovarian cancer patients

Benefits of Next Generation Sequencing (NGS) biomarker testing for cancer patients

Enrique de Álava, MD, PhD discusses the benefits of using NGS panels vs single-gene testing to guide treatment of non-small cell lung cancer patients (NSCLC) and explains the value of comprehensive genomic profiling (CGP) for accurate diagnosis and opportunities for precision medicine for cancer patients.

Clinical practice gaps in oncology precision medicine

Marni Tierno, PhD, RN, discusses the latest publications addressing clinical practice gaps presented at the panel discussion workshop held at the Association for Molecular Pathology (AMP) meeting on November 20, 2024, in Vancouver, BC, Canada.

Does finding a rare mutation accomplish anything?

Rachel E. Sanborn, MD, presents the journey of a patient diagnosed with atypical carcinoid with brain metastases who benefited from the detection of a RET fusion by comprehensive genomic profiling.

Testing for 𝘕𝘛𝘙𝘒 fusions

Vivek Subbiah, MD, explains how patients with rare and common tumors can benefit from next-generation-sequencing-based testing for NTRK gene fusions.
 

How can an Institution improve patient access to biomarker testing?

Nikoletta Sidiropoulos, MD describes the importance of institutional support to ensure equitable access to biomarker testing to improve cancer patient care.

Comprehensive genomic profiling utility in lung cancer

Prof. Tony Mok discusses the benefits of biomarker testing for patients with lung cancer. He provides an overview of the value of genomic profiling in the first-line setting and highlights the importance of detecting resistance mutations for personalized treatments.

What is the impact of insourcing NGS on patient care?

 Nikoletta Sidiropoulos, MD describes how insourcing next generation sequencing (NGS) improved patient care at her Institution. 

Publication Highlight

A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer

The BALLETT study shows that comprehensive genomic profiling (CGP) can be successfully integrated into routine cancer care across multiple hospitals in Belgium. Involving 872 patients with advanced cancers, the study found that 81% had actionable genetic markers—far more than the 21% identified through standard testing. With nine labs delivering results in under a month for most patients, and a national tumor board recommending matched treatments for nearly 70%, BALLETT proves that decentralized CGP is both feasible and impactful. It highlights the value of collaboration, standardization, and broad access to advanced diagnostics in improving patient care. Click the link to find out more.

Comprehensive Genomic Profiling - Liquid Biopsy

Video Hub

Clinical utility of ctDNA testing

Atocha Romero, PharmD, PhD, explains the value of liquid biopsy-based comprehensive genomic profiling.

ctDNA-guided treatment in colorectal cancer

Jeanne Tie, MD, discusses the DYNAMIC trial and areas of unmet needs for minimal residual disease (MRD) to become the standard of care for patients with colorectal cancer

Liquid biopsy NGS in cancer care

Pashtoon Kasi, MD, MS, explains how liquid biopsy next-generation-sequencing (NGS)-based  testing can benefit cancer patients.

Meet the Medical Affairs Team

Some info about the team's mission.
Email us

Whole Exome Sequencing, Whole Genome Sequencing, & Multiomics

Video hub
Advantages of comprehensive cancer whole exome sequencing
Nicole Pfarr, Dipl.-Biol, discusses how tumor whole exome sequencing (WES) can provide valuable insights into mechanisms that drive tumor proliferation, survival, and response to therapy. 
Whole-genome sequencing (WGS) in acute myeloid leukemia (AML)
Eric Duncavage, MD, explains how patients with AML can benefit from whole-genome sequencing testing at diagnosis and after treatment for minimal or measurable residual disease (MRD) assessment
Whole-genome sequencing (WGS) improves diagnosis of sarcomas
Felix Haglund and Magnus Carlsson discuss how whole-genome and transcriptome sequencing (WGTS) is transforming sarcoma diagnosis
CGP for clinical trial enrollment
Dr. Schilsky provides an overview of ASCO's TAPUR study and shares his perspective on a multi-omics approach for clinical trial design. 
Blog posts
A whole-genome-sequencing workflow with high sensitivity for MRD detection​

At the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, Illumina presents the ongoing development of a research-use-only WGS workflow for MRD detection.

Read moreOpens in a new window.
Whole-genome sequencing in AML diagnosis and monitoring

 

Whole-genome sequencing (WGS) has the potential to transform the diagnosis and management of AML. Read our article to learn more. 

 

Read moreOpens in a new window.
Whole-genome and whole-transcriptome sequencing for sarcoma diagnosis

 

Whole-genome and Whole-transcriptome sequencing (WGTS) improve the diagnosis of sarcomas. Read our article to learn more.

 

 

Read moreOpens in a new window.